Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor�…

Recent studies have revealed extensive genetic diversity both between and within tumours.
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a�…

Chromosomal instability (CIN)—which is a high rate of loss or gain of whole or parts of
chromosomes—is a characteristic of most human cancers and a cause of tumour aneuploidy�…

As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of�…

Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through
human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the�…

Deciphering whether actionable driver mutations are found in all or a subset of tumor cells
will likely be required to improve drug development and precision medicine strategies. We�…

Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective�…

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features�…

The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new�…

Chromosomal instability is a hallmark of cancer that results from ongoing errors in
chromosome segregation during mitosis. Although chromosomal instability is a major driver�…